Patents by Inventor Marc Whitlow
Marc Whitlow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7632504Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: GrantFiled: August 2, 2004Date of Patent: December 15, 2009Assignee: Enzon, Inc.Inventors: Marc Whitlow, Robert G. L. Shorr, David R. Filpula, Lihsyng Standford Lee
-
Patent number: 7150872Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: GrantFiled: August 10, 2004Date of Patent: December 19, 2006Assignee: Enzon, Inc.Inventors: Marc Whitlow, Robert G. L. Shorr, David R. Filpula, Lihsyng Standford Lee
-
Publication number: 20060063715Abstract: Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.Type: ApplicationFiled: September 29, 2005Publication date: March 23, 2006Inventors: Marc Whitlow, James Wood, Karl Hardman, Robert Bird, David Filpula, Michele Rollence
-
Patent number: 6872393Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: GrantFiled: February 26, 2001Date of Patent: March 29, 2005Assignee: Enzon, Inc.Inventors: Marc Whitlow, Robert G. L. Shorr, David R. Filpula, Lihsyng Standford Lee
-
Publication number: 20050048064Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: ApplicationFiled: August 2, 2004Publication date: March 3, 2005Inventors: Marc Whitlow, Robert Shorr, David Filpula, Lihsyng Lee
-
Publication number: 20050008650Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: ApplicationFiled: August 10, 2004Publication date: January 13, 2005Inventors: Marc Whitlow, Robert Shorr, David Filpula, Lihsyng Lee
-
Patent number: 6824782Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: GrantFiled: February 26, 2001Date of Patent: November 30, 2004Assignee: Enzon, Inc.Inventors: Marc Whitlow, Robert G. L. Shorr, David R. Filpula, Lihsyng Stanford Lee
-
Publication number: 20040132156Abstract: The present invention provides modified hepsin molecules, or fragments or derivatives thereof, including those having a substitute activation sequence. The modified hepsin molecules are cleaved at the substitute activation sequence, thereby generating activated modified hepsin molecule, or fragments or derivatives thereof, that exhibit the functional activity of naturally-occurring, wild-type hepsin molecules.Type: ApplicationFiled: October 2, 2003Publication date: July 8, 2004Applicant: Schering AktiengesellschaftInventors: Gordon Parry, David Vogel, Marc Whitlow, Qingyu Wu
-
Patent number: 6743908Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: GrantFiled: September 20, 2001Date of Patent: June 1, 2004Assignee: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Patent number: 6743896Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: GrantFiled: September 20, 2001Date of Patent: June 1, 2004Assignee: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Publication number: 20020161201Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: ApplicationFiled: September 20, 2001Publication date: October 31, 2002Applicant: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Publication number: 20020155498Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: ApplicationFiled: September 20, 2001Publication date: October 24, 2002Applicant: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Publication number: 20020098192Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: ApplicationFiled: February 26, 2001Publication date: July 25, 2002Applicant: ENZON, INC.Inventors: Marc Whitlow, Robert G.L. Shorr, David R. Filpula, Lihsyng Standford Lee
-
Publication number: 20020061307Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.Type: ApplicationFiled: February 26, 2001Publication date: May 23, 2002Applicant: ENZON, INC.Inventors: Marc Whitlow, Robert G.L. Shorr, David R. Filpula, Lihsyng Standford Lee
-
Patent number: 6323322Abstract: The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.Type: GrantFiled: April 30, 1998Date of Patent: November 27, 2001Assignee: Enzon, Inc.Inventors: David Filpula, Maoliang Wang, Robert Shorr, Marc Whitlow, Lihsyng S. Lee
-
Patent number: 5767260Abstract: Compositions of, genetic constructions coding for, and methods for producing single-chain and multivalent immunoeffector antigen-binding fusion proteins are provided by the invention. Antigen-binding fusion proteins having phospholipase A activating protein and/or tumor necrosis factor fragments are also provided by the invention. Genetic sequences coding for single-chain and multivalent immunoeffector antigen-binding fusion proteins are disclosed.Type: GrantFiled: August 16, 1995Date of Patent: June 16, 1998Assignee: Enzon Inc.Inventors: Marc Whitlow, David Filpula, Robert Shorr
-
Patent number: 5763733Abstract: Compositions of, genetic constructions coding for, and methods for producing single-chain and multivalent immunoeffector antigen-binding fusion proteins are provided by the invention. Antigen-binding fusion proteins having phospholipase A activating protein and/or tumor necrosis factor fragments are also provided by the invention. Genetic sequences coding for single-chain and multivalent immunoeffector antigen-binding fusion proteins are disclosed.Type: GrantFiled: October 13, 1994Date of Patent: June 9, 1998Assignee: Enzon, Inc.Inventors: Marc Whitlow, David Filpula, Robert Shorr